| BioClinica Announces First Quarter 2010 Financial Results (Business Wire) NEWTOWN, Pa.----BioClinicaâ„¢, Inc. , a global provider of clinical trial management services, today announced its financial results for the first quarter ended March 31, 2010. us.rd.yahoo.com |
Myriad Genetics: Growing Medical Diagnostics Franchise at Value Price SeekingValue submits: Myriad Genetics (MYGN) has been a Magic Formula stock for a while, and it keeps showing up in one of my Zack's screens (high current ratio, low P/E, trading near 52-week low), but I've always ignored it. I vaguely knew that they lost a patent case recently, so I figured the "bargain" the screens were turning up was bogus. For whatever reason, I finally decided to take a look last week, and I'm glad I did.First, the boilerplate description of the business:Complete Story » seekingalpha.com |
Investors Consider Biotech's Latest Results The Burrill Report submits: Earnings season is well underway with Gilead (GILD), Genzyme (GENZ), Biogen Idec, and Roche (RHHBY.PK) all having reported their second quarter results. The numbers have been a mixed bag and there are some big questions overhanging key players in the industry. Some investors are looking beyond the quarter, but what they see isn’t always encouraging. We spoke to Adam Feuerstein, senior columnist for The Street.com, about how the second quarter numbers are shaping up, what red flags may be out there, and how investors are looking at the results these days.Complete Story » seekingalpha.com |
Swapping Out a Deadly Gene In a boost to the resurgent field of gene therapy, a technique that fixed a defective gene has allowed a patient with a blood disorder to avoid blood transfusions for more than two years. online.wsj.com |
U.K. Reverses Stance On Alzheimer's Drugs The U.K.'s health-care costs watchdog said it aims to lift limits on the use of four Alzheimer's drugs by the state-funded National Health Service, a move that could benefit hundreds of thousands of people. online.wsj.com |